From the Research
The maximum dose of Adzenys (amphetamine extended-release orally disintegrating tablets) is 18.8 mg per day for adults and children 13 years and older, and 15.7 mg per day for children 6-12 years old. Adzenys is typically started at a lower dose and gradually increased as needed to achieve symptom control for ADHD. The medication should be taken once daily in the morning without food for consistent absorption. Patients should not exceed these maximum doses as higher amounts increase the risk of serious side effects including cardiovascular problems, growth suppression in children, and potential for abuse or dependence. Adzenys contains amphetamine, a stimulant that works by increasing levels of neurotransmitters like dopamine and norepinephrine in the brain to improve attention and reduce hyperactivity and impulsivity. Dose adjustments should only be made under medical supervision, and patients should be regularly monitored for effectiveness and side effects. According to the most recent study 1, amphetamine is associated with significant safety signals, including cardiovascular and neurological effects, and suicide-related adverse reactions. Therefore, it is crucial to carefully weigh the benefits and risks of Adzenys treatment and to closely monitor patients for any adverse effects.
Some key points to consider when prescribing Adzenys include:
- Starting with a lower dose and gradually increasing as needed to achieve symptom control
- Monitoring patients regularly for effectiveness and side effects
- Being aware of the potential for serious side effects, including cardiovascular problems and growth suppression in children
- Considering alternative treatment options for patients who may be at higher risk for adverse effects
- Ensuring that patients and their caregivers are educated about the potential risks and benefits of Adzenys treatment.
It is also important to note that the study 2 found that amphetamines increase blood pressure, heart rate, and withdrawals due to adverse effects, which should be taken into consideration when prescribing Adzenys. Additionally, the study 1 found that amphetamine is associated with significant safety signals, including cardiovascular and neurological effects, and suicide-related adverse reactions, which highlights the need for careful monitoring and risk assessment when prescribing Adzenys.